$1.62
1.25% day before yesterday
Nasdaq, Aug 22, 10:18 pm CET
ISIN
US12674W1099
Symbol
CABA

Cabaletta Bio Inc Stock price

$1.62
+0.04 2.53% 1M
-0.34 17.35% 6M
-0.65 28.63% YTD
-4.18 72.07% 1Y
-0.05 2.99% 3Y
-9.62 85.59% 5Y
-8.38 83.80% 10Y
-8.38 83.80% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.02 1.25%
ISIN
US12674W1099
Symbol
CABA
Industry

Key metrics

Basic
Market capitalization
$148.2m
Enterprise Value
$-26.2m
Net debt
positive
Cash
$194.7m
Shares outstanding
91.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 29.1
EV/Sales
- | negative
EV/FCF
0.2
P/B
0.8
Financial Health
Equity Ratio
82.3%
Return on Equity
-76.1%
ROCE
-81.7%
ROIC
-1,053.4%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$0.0 | $5.1m
EBITDA
$-144.5m | $-165.0m
EBIT
$-149.5m | $-154.4m
Net Income
$-144.3m | $-225.3m
Free Cash Flow
$-106.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-46.6% | -37.1%
EBIT
-49.3% | -23.4%
Net Income
-60.3% | -94.5%
Free Cash Flow
-40.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -3,235.5%
EBIT
-
Net
- | -4,417.4%
Free Cash Flow
-
More
EPS
$-2.3
FCF per Share
$-1.2
Short interest
6.7%
Employees
163
Rev per Employee
$0.0
Show more

Is Cabaletta Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Cabaletta Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Cabaletta Bio Inc forecast:

14x Buy
82%
3x Hold
18%

Analyst Opinions

17 Analysts have issued a Cabaletta Bio Inc forecast:

Buy
82%
Hold
18%

Financial data from Cabaletta Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
32% 32%
-
- Research and Development Expense 118 118
55% 55%
-
-145 -145
47% 47%
-
- Depreciation and Amortization 4.95 4.95
228% 228%
-
EBIT (Operating Income) EBIT -149 -149
49% 49%
-
Net Profit -144 -144
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cabaletta Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cabaletta Bio Inc Stock News

Neutral
The Motley Fool
16 days ago
Cabaletta Bio (CABA) Q2 Loss Widens 30%
Neutral
GlobeNewsWire
17 days ago
– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis –
Neutral
GlobeNewsWire
2 months ago
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of i...
More Cabaletta Bio Inc News

Company Profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Head office United States
CEO Steven Nichtberger
Employees 163
Founded 2017
Website www.cabalettabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today